• Celldex presented long-term Phase 2 results for barzolvolimab at the EAACI annual meeting, highlighting sustained off-treatment improvement in CSU-related angioedema.
• Patients showed rapid relief during treatment, with benefits persisting months after dosing ended, supporting a potential shift beyond symptom control.
• Two Phase 3 CSU trials are fully enrolled, with topline results expected in Q4 2026, positioning the program for a planned 2027 BLA filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606141021PRIMZONEFULLFEED9746580) on June 14, 2026, and is solely responsible for the information contained therein.